M&A Deal Summary

Bio-Rad Acquires AbD Serotec

On January 10, 2013, Bio-Rad acquired life science company AbD Serotec from MorphoSys for 53M EUR

Acquisition Highlights
  • This is Bio-Rad’s 4th transaction in the Life Science sector.
  • This is Bio-Rad’s 3rd largest (disclosed) transaction.
  • This is Bio-Rad’s 3rd transaction in the United States.
  • This is Bio-Rad’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2013-01-10
Target AbD Serotec
Sector Life Science
Buyer(s) Bio-Rad
Sellers(s) MorphoSys
Deal Type Divestiture
Deal Value 53M EUR

Target

AbD Serotec

Raleigh, North Carolina, United States
AbD Serotec, Inc. is a manufacturer of antibodies.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bio-Rad

Hercules, California, United States
Category Company
Founded 1952
Sector Medical Products
Employees8,000
Revenue 2.7B USD (2023)
DESCRIPTION

Bio-Rad is a developer, manufacturer, and marketer of a broad range of medical tools and services to the life science research and clinical diagnostics markets. Bio-Rad was incorporated in 1952 and is based in Hercules, California.

DEAL STATS #
Overall 4 of 8
Sector (Life Science) 4 of 7
Type (Divestiture) 1 of 2
State (North Carolina) 1 of 1
Country (United States) 3 of 6
Year (2013) 1 of 1
Size (of disclosed) 3 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-10-05 QuantaLife

Pleasanton, California, United States

QuantaLife, Inc. is a life science company that manufactures and markets products based on their proprietary nucleic acid testing method.

Buy $162M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-04-10 GnuBIO

Cambridge, Massachusetts, United States

GnuBIO, Inc., is a privately-held life sciences company that has developed a droplet-based DNA sequencing platform. The innovative system developed by GnuBIO allows for a fully-integrated DNA sequencing platform that utilizes microfluidic and emulsion technology to perform complex, multiplexed reactions in droplets. This will allow both researchers and clinicians in the future to perform complete DNA sequencing workflows in a few hours instead of days.

Buy -

Seller(S) 1

SELLER

MorphoSys

Planegg, Germany
Category Company
Founded 1992
Sector Life Science
Revenue 278M EUR (2022)
DESCRIPTION

MorphoSys is a global biopharmaceutical company developing innovative medicines in oncology. MorphoSys was formed in 1992 and is based in Planegg, Germany.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (North Carolina) 1 of 1
Country (United States) 1 of 1
Year (2013) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-10-15 Lanthio Pharma - Lanthipeptide Technology

Netherlands

Buy -
Mergr

Product

Company

Legal